Pyrrolobenzodiazepines

Details Pyrrolobenzodiazepines Pyrrolobenzodiazepines

2003-11-14

2008-08-05

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S496000

Reexamination Certificate

active

07407951

ABSTRACT:
Compounds of formula (I): formula (I) and salts, solvates, chemically protected forms, and prodrugs thereof, are disclosed wherein R2is selected from: an optionally substituted napthyl group; an optionally substituted thiophenyl or furanyl group; and a phenyl group substituted by: one or more chloro or fluoro groups; an ethyl or propyl group; a 4-t-butyl group; a 2-methyl group; or two methyl groups in the 2- and 6-positions.

REFERENCES:
patent: 3523941 (1970-08-01), Leimgruber et al.
patent: 3524849 (1970-08-01), Batcho et al.
patent: 4185016 (1980-01-01), Takanabe et al.
patent: 4239683 (1980-12-01), Takanabe et al.
patent: 4309437 (1982-01-01), Ueda et al.
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5545568 (1996-08-01), Ellman et al.
patent: 6562806 (2003-05-01), Thurston et al.
patent: 6608192 (2003-08-01), Thurston et al.
patent: 6660856 (2003-12-01), Wang
patent: 6747144 (2004-06-01), Thurston et al.
patent: 2003/0120069 (2003-06-01), Thurston et al.
patent: 2003/0195196 (2003-10-01), Thurston et al.
patent: 2004/0092736 (2004-05-01), Thurston et al.
patent: 2004/0198722 (2004-10-01), Thurston et al.
patent: 0239400 (1987-09-01), None
patent: 1193270 (2002-04-01), None
patent: 2027356 (1969-12-01), None
patent: 2586683 (1987-03-01), None
patent: 1299198 (1972-12-01), None
patent: 2053894 (1981-02-01), None
patent: 53-82792 (1978-07-01), None
patent: 57131791 (1982-08-01), None
patent: 58180487 (1983-10-01), None
patent: WO 88/04659 (1988-06-01), None
patent: WO 88/07378 (1988-10-01), None
patent: WO 89/10140 (1989-11-01), None
patent: WO 91/16324 (1991-10-01), None
patent: WO 92/19620 (1992-11-01), None
patent: WO 93/08288 (1993-04-01), None
patent: WO 93/18045 (1993-09-01), None
patent: WO 96/23497 (1996-08-01), None
patent: WO 97/01560 (1997-01-01), None
patent: WO 97/07097 (1997-02-01), None
patent: WO 98/11101 (1998-03-01), None
patent: WO 98/12197 (1998-03-01), None
patent: WO 99/29642 (1999-06-01), None
patent: WO 99/46244 (1999-09-01), None
patent: WO 00/12506 (2000-03-01), None
patent: WO 00/12507 (2000-03-01), None
patent: WO 00/12508 (2000-03-01), None
patent: WO 00/12509 (2000-03-01), None
patent: WO 00/64864 (2000-11-01), None
patent: WO 2004/043963 (2004-05-01), None
patent: WO 2005/023814 (2005-03-01), None
patent: WO 2005/040170 (2005-05-01), None
patent: WO 2005/085251 (2005-09-01), None
Albericio, F. et al., “NPE-Resin, A New Approach to the Solid-Phase Synthesis of Protected Peptides and Oligonucleotides II. Synthesis of Protected Peptides1,2,”Tetrahedron Letters, 32:1515-1518 (1991).
Albericio, F. et al., “NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides,”Peptides1990, Proc. 21.sub.st Eur. Pept. Symp., 134-136 (1990).
Althius, T. H. and Hess, H. J., “Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat,”0J. Medicinal Chem., 20(1), 146-148 (1977).
Arima et al., “Studies on Tomaymycin, a New Antibiotic. I. Isolation and Properties of Tomaymycin,”J. Antibiotics, 25, 437-444 (1972).
Aristoff, J. and Johnson, P., “Synthesis of CBI-PDE-I-Dimer, the Benzannelated Analogue of CC-1065,”J. Org. Chem., 57, 6234-6239 (1992).
Bagshawe et al., “Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites,”Antibody, Immunoconjugates, and Radiopharmaceuticals, 4, 915-922 (1991).
Baraldi, P.G. et al., “Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid,”Bioorganic&Medicinal Chemistry Letters, vol. 8, No. 21, 3019-3024 (1998).
Baraldi, P.G. et al., “Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers,”J. Med. Chem., 42, 5131-5141 (1999).
Bayley, H. et al., “Photoactivatable drugs,”TIPS, 8, 138-143 (1987).
Berry, J. M. et al., “Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines,”Tetrahedron Letters, 41, 6171-6174 (2000).
Bi, Y. et al., “Building blocks for peptide and carbamate libraries”,Bioorganic&Medicinal Chemistry Letters, vol. 6, No. 19, 2299-2300 (1996).
Bi, Y., et al., “Building blocks for peptide and carbamate libraries,”Chemical Abstracts, vol. 125, No. 23, 1013 (1996).
Boger et al., “CC-1065 and the Duocarmycins: Synthetic Studies,”Chem. Rev., 97, 787-828 (1997).
Bose et al., “New Approaches to Pyrrolo[2,1-c][1,4]benzodiazepines: Synthesis, DNA-binding and cytotoxicity of DC-81,”Tetrahedron, 48, 751-758 (1992).
Bose, D.S. et al., “Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System,”J. Am. Chem. Soc., 114, 4939-4941 (1992).
Bridges, R.J. et al., “Conformationally Defined Neurotransmitter Analogues. Selective Inhibition of Glutamate Uptake by One Pyrrolidine-2,4-dicarboxylate Diastereomer,”J. Med. Chem., 34, 717-725 (1991).
Brown, S.C. et al., “NMR Solution Structure of a Peptide Nucleic Acid Complexed with RNA,”Science, 265, 777-780 (1994).
Bundgaard, H., “Design and Application of Prodrugs,”A Textbook of Drug Design and Development, eds Krogsgaard-Lassen, P., and Bundgaard, H., Harwood Academic Press, 113-135 (1991).
Burgess, K. et al., “Solid Phase Synthesis of Oligoureas”,J.Ame. Chem. Soc., 119: 1556-1564 (1997).
Burgess, K et al., “Solid Phase Synthesis of Unnatural Biopolymers Containing Repeating Urea Units,”Agnew Chem. Int. Ed. Engl, 34, No. 8:907-909 (1995).
Carruth, J.A.S., “Clinical applications for photodynamic therapy,”J. Photochem Photobiol., 9, 396-397 (1991).
Cho, C Y et al., “An Unnatural Biopolymer”,Science, 261: 1303-1305 (1993).
Courtney, S. M. et al., “A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines”,Tetrahedron Letters, vol. 34, No. 33, 5327-28 (1993).
Culver et al., “In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science, 256, 1550-1552 (1992).
Dalton, S. and Treisman, R, “Characterization of SAP-1, a Protein Recruited by Serum Response Factor to thec-fosSerum Response Element,”Cell, 68, 597-612 (1992).
Damayanthi, Y., et al., “Design and synthesis of novel pyrrolo [2,1-c][1,4] benzodiazepine-Lexitropsin Conjugates,”J. Org. Chem., 64, 290-292 (1999).
Dangles, O. et al., “Selective Cleavage of the Allyl and Allyloxycarbonyl Groups through Palladium-Catalyzed Hydrostannolysis with Tributyltin Hydride. Application to the Selective Protection-Deprotection of Amino Acid Derivatives and in Peptide Synthesis,”J. Org. Chem., 52, 4984-4993 (1987).
Dressman, B.A., et al., “Solid Phase Synthesis of Hydantoins Using a Carbamate Linker and a Novel Cyclization/Cleavage Step,”Tetrahedron Letters, 937-940 (1996).
Drost, K.J. and Cava, M.P., “A Photochemically Based Synthesis of the Benzannelated Analogue of the CC-1065 A Unit,”J. Org. Chem., 56:2240-2224 (1991).
Eashoo, M. et al., “Fibers from a Low Dielectric Constant Fluorinated Polyimide: Solution Spinning and Morphology Control,”J. Polymer Science, 35:173-185 (1997).
Edman, P. and Begg, G., “A Protein Sequenator,”Eur. J. Biochem., 1, 80-91 (1967).
Egholm, M et al., “Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone,”J. Am. Chem. Soc., 114, 1895-1897 (1992).
Egholm, M et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules,”Nature, 365, 566-568 (1993).
Englehardt et al., “Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses,”Nature Genetics, 4, 27-34 (1993).
Farmer, J.D. et a

Affiliated with

Also associated with

Rating

Pyrrolobenzodiazepines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolobenzodiazepines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolobenzodiazepines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3998634